CYTK — Cytokinetics Inc

Cytokinetics Inc (CYTK) is a biotechnology company listed on NASDAQ. It is led by Robert I. Blum, based in 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, with about 498 employees. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Latest reported CYTK revenue for 2025-09-30 was $1.9M. Net income was -$601.9M. Revenue was down 97.1% from 2025-06-30 to 2025-09-30. CYTK currently screens at market cap $4.05B.

Use this CYTK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CYTK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CYTK SEC filings page. Lician reads the product cache first so this HTML stays unique to Cytokinetics Inc even when a live quote feed is slow.